Ran Nussbaum Net Worth & Insider Trades

Ran Nussbaum - Director, Keros Therapeutics, Inc

As of June 3, 2022

What is Ran Nussbaum's Net Worth?

The current estimated net worth of Keros Therapeutics, Inc's Director, Ran Nussbaum, is estimated to be about $77.15M . Ran Nussbaum owns about 155,262 units of Keros Therapeutics, Inc common stock. In the last 2 years at Keros Therapeutics, Inc, Ran Nussbaum has sold an estimated value of $0 worth.

What is Ran Nussbaum's Past Insider Trading?

Ran Nussbaum's largest purchase order was 3,982,599 units , worth over $7M on April 13, 2020. In total, Ran Nussbaum has made about 4 transactions over 2 years of their time at Keros Therapeutics, Inc. Ran Nussbaum usually trades in June, with the busiest year in 2020. The most recent transaction was a purchase order of 60,000 units , worth over $3M on November 19, 2020.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Ran Nussbaum's' Mailing Address?

  • Mailing address is C/o Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404 CA

Keros Therapeutics, Inc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Jasbir Seehra, Ph.D. 2020 $521,014 $8,713,137 $262,650 $3,498 $9,500,299
Jasbir Seehra, Ph.D. 2019 $485,100 $15,379 $194,040 - $694,519
Keith Regnante 2020 $323,170 $1,901,352 $138,000 $521 $2,363,042
Jennifer Lachey, Ph.D. 2020 $370,196 $3,017,362 $154,200 $521 $3,542,278
Jennifer Lachey, Ph.D. 2019 $294,255 $27,039 $93,000 - $414,294
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1664710/000110465921051967/tm2112429-1_def14a.htm

What are Keros Therapeutics, Inc's Past Insider Trades?

Keros Therapeutics, Inc's most recent insider trade came on July 19, 2022 by Jennifer Lachey who sold 46,034 units worth $1.38M . In the last 2 years, insiders at Keros Therapeutics, Inc have sold an estimated value of $35.47M and bought an estimated value of $46.26M worth of shares. Insider trading is most common in April, with the busiest year in 2021. The most active traders at the company are Jennifer Lachey, Chief Scientific Officer,  Julius Knowles, Director,  and Claudia Ordonez, Chief Medical Officer .

Keros Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1